A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML

Trial Profile

A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs CDX 1401 (Primary) ; Decitabine (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 19 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
    • 08 Feb 2018 Planned initiation date changed from 31 Jan 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top